ATE427745T1 - Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus - Google Patents

Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus

Info

Publication number
ATE427745T1
ATE427745T1 AT02789421T AT02789421T ATE427745T1 AT E427745 T1 ATE427745 T1 AT E427745T1 AT 02789421 T AT02789421 T AT 02789421T AT 02789421 T AT02789421 T AT 02789421T AT E427745 T1 ATE427745 T1 AT E427745T1
Authority
AT
Austria
Prior art keywords
methods
therapies
compositions
treating
alcoholsm
Prior art date
Application number
AT02789421T
Other languages
English (en)
Inventor
Seth Lederman
Original Assignee
Krele Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krele Pharmaceuticals Llc filed Critical Krele Pharmaceuticals Llc
Application granted granted Critical
Publication of ATE427745T1 publication Critical patent/ATE427745T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
AT02789421T 2001-11-05 2002-11-04 Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus ATE427745T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33890101P 2001-11-05 2001-11-05

Publications (1)

Publication Number Publication Date
ATE427745T1 true ATE427745T1 (de) 2009-04-15

Family

ID=23326616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02789421T ATE427745T1 (de) 2001-11-05 2002-11-04 Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus

Country Status (10)

Country Link
US (3) US20030087814A1 (de)
EP (1) EP1441708B1 (de)
AT (1) ATE427745T1 (de)
AU (1) AU2002354017B2 (de)
CA (1) CA2463987C (de)
DE (1) DE60231896D1 (de)
DK (1) DK1441708T3 (de)
NZ (1) NZ532583A (de)
PT (1) PT1441708E (de)
WO (1) WO2003039525A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231896D1 (de) 2001-11-05 2009-05-20 Krele Pharmaceuticals Llc Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
NZ577460A (en) * 2006-12-14 2012-01-12 Teva Pharma Crystalline solid rasagiline base
EP2299993A4 (de) * 2008-06-19 2014-08-20 Teva Pharma Verfahren zum reinigen einer rasagilin-base
NO2501234T3 (de) * 2009-11-20 2018-02-10
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US20130165511A1 (en) * 2010-09-01 2013-06-27 TONIX Pharmaceuticals Holding Corp Treatment for cocaine addiction
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
LT3650081T (lt) 2013-03-15 2024-06-10 Tonix Pharma Holdings Limited Eutektinės ciklobenzaprino hidrochlorido ir manitolio vaistinės formos
EP3193854A4 (de) 2014-09-18 2018-05-02 Tonix Pharma Holdings Limited Eutektische formulierungen von cyclobenzaprin-hydrochlorid
CN111447971A (zh) 2017-12-11 2020-07-24 通尼克斯制药控股有限公司 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2567814A (en) 1948-03-26 1951-09-11 Ayerst Mckenna & Harrison Tetraethyl thiuram disulfide alcoholism treatment composition
US3155584A (en) * 1962-12-03 1964-11-03 Abbott Lab Compositions and method of inhibiting monoamine oxidase and treating hypertension
SE404186B (sv) * 1975-06-09 1978-09-25 Astra Laekemedel Ab Forfarande for framstellning av cyklopropanolderivat
US4678809A (en) 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US4565689A (en) * 1985-04-12 1986-01-21 Wirth Maschinen-Und Bohrgerate-Fabrik Gmbh Method for treating the effects of alcohol
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US4868218A (en) * 1987-08-18 1989-09-19 Buyske Donald A Method of treating depression
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
AU8760691A (en) * 1990-10-01 1992-04-28 Thomas E. Radecki Drug therapy for alcohol abusers
HU209605B (en) 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
AU1992592A (en) * 1991-05-24 1993-01-08 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
EP0520325A1 (de) 1991-06-28 1992-12-30 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
EP0593807A1 (de) 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH & Co. KG Transdermales Pflaster zur Abgabe von basischen, flüchtigen pharmazeutischen Wirkstoffen und Verfahren zu ihrer Herstellung
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
DE4428444A1 (de) 1994-08-11 1996-02-15 Dresden Arzneimittel Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
BR9501972A (pt) * 1995-05-09 1997-08-26 Tostes Luiz Roberto Mallat Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo
CN1116870C (zh) 1996-03-15 2003-08-06 萨默塞特药品有限公司 司立吉林在制备用于预防或治疗外周神经病的药物中的应用
DE69614888D1 (de) * 1996-06-28 2001-10-04 Dallet Etienne Romeuf Sauze Au Durch muskelkraft angebtriebenen fahrzeug, insbesondere fahrrad
US6255497B1 (en) * 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
KR20010031470A (ko) 1997-10-28 2001-04-16 둘락 노먼 씨. 포유동물의 갈망을 감소시키는 방법
CA2334830A1 (en) * 1998-05-12 1999-11-18 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
DE60231896D1 (de) 2001-11-05 2009-05-20 Krele Pharmaceuticals Llc Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus

Also Published As

Publication number Publication date
DE60231896D1 (de) 2009-05-20
EP1441708A1 (de) 2004-08-04
EP1441708B1 (de) 2009-04-08
CA2463987A1 (en) 2003-05-15
PT1441708E (pt) 2009-06-18
NZ532583A (en) 2006-12-22
DK1441708T3 (da) 2009-07-06
US20090005441A1 (en) 2009-01-01
AU2002354017B2 (en) 2007-08-16
US8481599B2 (en) 2013-07-09
US20030087814A1 (en) 2003-05-08
EP1441708A4 (de) 2007-05-23
WO2003039525A1 (en) 2003-05-15
US8093300B2 (en) 2012-01-10
CA2463987C (en) 2011-03-08
US20120101154A1 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
HUP0200492A2 (hu) Eljárás retinoid bőrkárosodás gátlására
ATE427745T1 (de) Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
WO2005000213A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
SE0301886D0 (sv) New use V
ATE376446T1 (de) Verwendung von n-hydroxyalkyl-o-benzylchitosanen zur haarbehandlung
PL375900A1 (en) Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
DK0942751T3 (da) Præparater til behandling af perifere nuropatier indeholdende antidepressiver og/eller monoaminoxidase-inhibitorer og/eller vitamin B12 og/eller prekursere til eller inducere af en neurotransmitter
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
ATE495735T1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
ATE382346T1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
WO2005018535A3 (en) Compositions and methods for treatment of severe acute respiratory syndrome (sars)
ATE212552T1 (de) Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
ATE451106T1 (de) Behandlung von sti571-resistenter oder - intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen
DE60334094D1 (de) Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
SE0301883D0 (sv) New use II
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1441708

Country of ref document: EP